TITLE

Reduced Coronary Artery and Abdominal Aortic Calcification in Hispanics With Type 2 Diabetes

AUTHOR(S)
Reaven, Peter D.; Sacks, Jerome
PUB. DATE
May 2004
SOURCE
Diabetes Care;May2004, Vol. 27 Issue 5, p1115
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE — To compare lifestyle factors, cardiovascular risk factors, and coronary artery calcium (CAC) and abdominal aortic calcium (AAC) levels in Hispanic and non-Hispanic white (NHW) individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS — We recently demonstrated in a small group of nonreferred, healthy, nondiabetic subjects that CAC was reduced in Hispanics compared with NHWs, despite a worse cardiovascular risk factor profile. In this study, we evaluated whether this ethnic disparity in vascular calcification was present in individuals with type 2 diabetes and in several different arterial beds. Hispanic and NHW subjects (n = 245) with type 2 diabetes were evaluated for cardiovascular risk factors using questionnaires and assays of plasma biomarkers. CAC and AAC were measured by electron-beam computer-assisted tomography. RESULTS — Although Hispanics were slightly younger than NHWs, other standard risk factors and novel cardiovascular risk factors, including plasminogen activator-1 and fibrinogen levels, were similar between the groups. Despite the similar risk factor profile, the prevalence of cardiovascular disease (CVD) and mean and median levels of CAC and AAC were lower in Hispanics. Furthermore, the distribution of these calcium scores differed from that of NHWs (P < 0.05), with significantly fewer Hispanic subjects having high CAC or AAC scores. These differences were not explained by differences in CVD prevalence or any measured lifestyle or risk factor. CONCLUSIONS — Hispanics with type 2 diabetes have reduced CAC and AAC levels compared with NHW subjects, suggesting a reduction in the overall burden of vascular calcification and atherosclerosis. These data are consistent with the notion that Hispanics are protected against the development of CVD.
ACCESSION #
12986987

 

Related Articles

  • Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Home, P. D.; Pocock, S. J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Dargie, H.; Komajda, M.; Gubb, J.; Biswas, N.; Jones, N. P. // Diabetologia;Sep2005, Vol. 48 Issue 9, p1726 

    Aims/hypothesis: Studies suggest that in addition to blood glucose concentrations, thiazolidinediones such as rosiglitazone improve some cardiovascular (CV) risk factors and surrogate markers, that are abnormal in type 2 diabetes. However, fluid retention might lead to cardiac failure in a...

  • Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cea-Calvo, Luis; Conthe, Pedro; Gómez-Fernández, Pablo; De Alvaro, Fernando; Fernández-Pérez, Cristina // Cardiovascular Diabetology;2006, Vol. 5, p23 

    Background: Target organ damage (mainly cardiac and renal damage) is easy to evaluate in outpatient clinics and offers valuable information about patient's cardiovascular risk. The purpose of this study was to evaluate, using simple methods, the prevalence of cardiac and renal damage and its...

  • Infection Control Update.  // Healthcare Purchasing News;Apr2011, Vol. 34 Issue 4, p26 

    The article reports on research which found that type two diabetes can reduce a person's life span by six years as a result of increasing the person's risk for several diseases including cardiovascular disease, cancer and liver disease.

  • Cross-Sectional and Prospective Associations Between Proinsulin and Cardiovascular Disease Risk Factors in a Population Experiencing Rapid Cultural Transition. McKeown-Eyssen, Gail; Hanley, Anthony J. G.; Harris, Stewart B.; Hegele, Robert A.; Wolever, Thomas M.S.; Kwan, Jeremy; Connelly, Philip W.; Zinman, Bernard // Diabetes Care;Jul2001, Vol. 24 Issue 7, p1240 

    Presents a study which examined cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors using data from a sample population of type 2 diabetics in a Native Canadian community. Research design and methods; Results; Conclusions.

  • Randomized Controlled Community-Based Nutrition and Exercise Intervention Improves Glycemia and Cardiovascular Risk Factors in Type 2 Diabetic Patients in Rural Costa Rica. Goldhaber-Fiebert, Jeremy D.; Goldhaber-Fiebert, Sara N.; Tristán, Mario L.; Nathan, David M. // Diabetes Care;Jan2003, Vol. 26 Issue 1, p24 

    OBJECTIVE — The prevalence of type 2 diabetes, especially in developing countries, has grown over the past decades. We performed a controlled clinical study to determine whether a community-based, group-centered public health intervention addressing nutrition and exercise can ameliorate...

  • The pluses and minuses of ADDITION-Europe. Sattar, Naveed // Diabetes Digest;2011, Vol. 10 Issue 4, p205 

    The article offers information on the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen Detected Diabetes in Primary Care (ADDITION)-Europe. It says that the study has been considered as negative due to the lesser efficacy of intensive treatment as compared to...

  • Perspective: Prescribing advisors. Newland-Jones, Philip // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on the increased cardiovascular disease risk associated with the use of the glucose-lowering agent sulphonylurea. He believes that formulary developers and prescribing advisors should be aware of the risks of hypoglycaemia prior to prescribing sulphonylureas. He suggests...

  • Management of Type 2 Diabetes Mellitus and Cardiovascular Risk: Lessons from Intervention Trials. Yki-Järvinen, H. // Drugs;Nov2000, Vol. 60 Issue 5, p975 

    Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data...

  • Saxagliptin does not increase risk of CV events.  // Reactions Weekly;Nov2015, Vol. 1578 Issue 1, p10 

    The article presents a study which shows that saxagliptin does not increase cardiovascular (CV) risk events in patients having type 2 diabetes mellitus irrespective of glycaemic control.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics